Multi-tyrosine kinase inhibitor

DRUG CLASS:

Multi-tyrosine kinase inhibitor

News alerts, weekly reports and conference planners

Related drugs:

‹

›

No biomarker	Renal Cell Carcinoma	No biomarker	Renal Cell Carcinoma	nivolumab + cabozantinib tablet Sensitive: A1 - Approval nivolumab + cabozantinib tablet Sensitive : A1	nivolumab + cabozantinib tablet Sensitive: A1 - Approval nivolumab + cabozantinib tablet Sensitive : A1
FLT3 mutation	Acute Myelogenous Leukemia	FLT3 mutation	Acute Myelogenous Leukemia	gilteritinib Sensitive: A1 - Approval gilteritinib Sensitive : A1	gilteritinib Sensitive: A1 - Approval gilteritinib Sensitive : A1
No biomarker	Thyroid Gland Medullary Carcinoma	No biomarker	Thyroid Gland Medullary Carcinoma	cabozantinib capsule Sensitive: A1 - Approval cabozantinib capsule Sensitive : A1	cabozantinib capsule Sensitive: A1 - Approval cabozantinib capsule Sensitive : A1
NTRK1 fusion	Solid Tumor	NTRK1 fusion	Solid Tumor	repotrectinib Sensitive: A1 - Approval repotrectinib Sensitive : A1	repotrectinib Sensitive: A1 - Approval repotrectinib Sensitive : A1
NTRK3 fusion	Solid Tumor	NTRK3 fusion	Solid Tumor	repotrectinib Sensitive: A1 - Approval repotrectinib Sensitive : A1	repotrectinib Sensitive: A1 - Approval repotrectinib Sensitive : A1
NTRK2 fusion	Solid Tumor	NTRK2 fusion	Solid Tumor	repotrectinib Sensitive: A1 - Approval repotrectinib Sensitive : A1	repotrectinib Sensitive: A1 - Approval repotrectinib Sensitive : A1
No biomarker	Thyroid Gland Carcinoma	No biomarker	Thyroid Gland Carcinoma	cabozantinib tablet Sensitive: A1 - Approval cabozantinib tablet Sensitive : A1	cabozantinib tablet Sensitive: A1 - Approval cabozantinib tablet Sensitive : A1
FLT3 mutation	Acute Myelogenous Leukemia	FLT3 mutation	Acute Myelogenous Leukemia	midostaurin Sensitive: A1 - Approval midostaurin Sensitive : A1	midostaurin Sensitive: A1 - Approval midostaurin Sensitive : A1
BCR-ABL1 T315I	Chronic Myeloid Leukemia	BCR-ABL1 T315I	Chronic Myeloid Leukemia	ponatinib Sensitive: A1 - Approval ponatinib Sensitive : A1	ponatinib Sensitive: A1 - Approval ponatinib Sensitive : A1
BCR-ABL1 T315I	Acute Lymphocytic Leukemia	BCR-ABL1 T315I	Acute Lymphocytic Leukemia	ponatinib Sensitive: A1 - Approval ponatinib Sensitive : A1	ponatinib Sensitive: A1 - Approval ponatinib Sensitive : A1
No biomarker	Chronic Myeloid Leukemia	No biomarker	Chronic Myeloid Leukemia	ponatinib Sensitive: A1 - Approval ponatinib Sensitive : A1	ponatinib Sensitive: A1 - Approval ponatinib Sensitive : A1
No biomarker	Thyroid Gland Hurthle Cell Carcinoma	No biomarker	Thyroid Gland Hurthle Cell Carcinoma	sorafenib Sensitive: A1 - Approval sorafenib Sensitive : A1	sorafenib Sensitive: A1 - Approval sorafenib Sensitive : A1
No biomarker	Thyroid Gland Follicular Carcinoma	No biomarker	Thyroid Gland Follicular Carcinoma	sorafenib Sensitive: A1 - Approval sorafenib Sensitive : A1	sorafenib Sensitive: A1 - Approval sorafenib Sensitive : A1
No biomarker	Thyroid Gland Papillary Carcinoma	No biomarker	Thyroid Gland Papillary Carcinoma	sorafenib Sensitive: A1 - Approval sorafenib Sensitive : A1	sorafenib Sensitive: A1 - Approval sorafenib Sensitive : A1
No biomarker	Renal Cell Carcinoma	No biomarker	Renal Cell Carcinoma	sorafenib Sensitive: A1 - Approval sorafenib Sensitive : A1	sorafenib Sensitive: A1 - Approval sorafenib Sensitive : A1
No biomarker	Thyroid Gland Medullary Carcinoma	No biomarker	Thyroid Gland Medullary Carcinoma	vandetanib Sensitive: A1 - Approval vandetanib Sensitive : A1	vandetanib Sensitive: A1 - Approval vandetanib Sensitive : A1
BCR-ABL1 fusion	Acute Lymphocytic Leukemia	BCR-ABL1 fusion	Acute Lymphocytic Leukemia	ponatinib Sensitive: A1 - Approval ponatinib Sensitive : A1	ponatinib Sensitive: A1 - Approval ponatinib Sensitive : A1
ABL1 T315I	Chronic Myeloid Leukemia	ABL1 T315I	Chronic Myeloid Leukemia	ponatinib Sensitive: A1 - Approval ponatinib Sensitive : A1	ponatinib Sensitive: A1 - Approval ponatinib Sensitive : A1
ROS1 positive	Non Small Cell Lung Cancer	ROS1 positive	Non Small Cell Lung Cancer	repotrectinib Sensitive: A1 - Approval repotrectinib Sensitive : A1	repotrectinib Sensitive: A1 - Approval repotrectinib Sensitive : A1
No biomarker	Lung Adenocarcinoma	No biomarker	Lung Adenocarcinoma	nintedanib Sensitive: A1 - Approval nintedanib Sensitive : A1	nintedanib Sensitive: A1 - Approval nintedanib Sensitive : A1
No biomarker	Hepatocellular Cancer	No biomarker	Hepatocellular Cancer	cabozantinib tablet Sensitive: A1 - Approval cabozantinib tablet Sensitive : A1	cabozantinib tablet Sensitive: A1 - Approval cabozantinib tablet Sensitive : A1
No biomarker	Renal Cell Carcinoma	No biomarker	Renal Cell Carcinoma	cabozantinib tablet Sensitive: A1 - Approval cabozantinib tablet Sensitive : A1	cabozantinib tablet Sensitive: A1 - Approval cabozantinib tablet Sensitive : A1
No biomarker	Hepatocellular Cancer	No biomarker	Hepatocellular Cancer	regorafenib Sensitive: A1 - Approval regorafenib Sensitive : A1	regorafenib Sensitive: A1 - Approval regorafenib Sensitive : A1
No biomarker	Hepatocellular Cancer	No biomarker	Hepatocellular Cancer	sorafenib Sensitive: A1 - Approval sorafenib Sensitive : A1	sorafenib Sensitive: A1 - Approval sorafenib Sensitive : A1
No biomarker	Soft Tissue Sarcoma	No biomarker	Soft Tissue Sarcoma	pazopanib Sensitive: A1 - Approval pazopanib Sensitive : A1	pazopanib Sensitive: A1 - Approval pazopanib Sensitive : A1
No biomarker	Gastrointestinal Stromal Tumor	No biomarker	Gastrointestinal Stromal Tumor	regorafenib Sensitive: A1 - Approval regorafenib Sensitive : A1	regorafenib Sensitive: A1 - Approval regorafenib Sensitive : A1
No biomarker	Renal Cell Carcinoma	No biomarker	Renal Cell Carcinoma	pazopanib Sensitive: A1 - Approval pazopanib Sensitive : A1	pazopanib Sensitive: A1 - Approval pazopanib Sensitive : A1
No biomarker	Colorectal Cancer	No biomarker	Colorectal Cancer	regorafenib Sensitive: A1 - Approval regorafenib Sensitive : A1	regorafenib Sensitive: A1 - Approval regorafenib Sensitive : A1
RAS wild-type	Colorectal Cancer	RAS wild-type	Colorectal Cancer	regorafenib Sensitive: A1 - Approval regorafenib Sensitive : A1	regorafenib Sensitive: A1 - Approval regorafenib Sensitive : A1
No biomarker	Osteosarcoma	No biomarker	Osteosarcoma	regorafenib Sensitive: A2 - Guideline regorafenib Sensitive : A2	regorafenib Sensitive: A2 - Guideline regorafenib Sensitive : A2
FLT3-TKD mutation	Acute Myelogenous Leukemia	FLT3-TKD mutation	Acute Myelogenous Leukemia	midostaurin Sensitive: A2 - Guideline midostaurin Sensitive : A2	midostaurin Sensitive: A2 - Guideline midostaurin Sensitive : A2
FLT3-ITD mutation	Acute Myelogenous Leukemia	FLT3-ITD mutation	Acute Myelogenous Leukemia	midostaurin Sensitive: A2 - Guideline midostaurin Sensitive : A2	midostaurin Sensitive: A2 - Guideline midostaurin Sensitive : A2

Multi-tyrosine kinase inhibitor

Multi-tyrosine kinase inhibitor

Associations(891)

Associations
(891)